Kresowik Timothy F, Bratzler Dale W, Kresowik Rebecca A, Hendel Marc E, Grund Sherry L, Brown Kellie R, Nilasena David S
University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
J Vasc Surg. 2004 Feb;39(2):372-80. doi: 10.1016/j.jvs.2003.09.023.
The purpose of this study was to assess the effect of community-wide performance measurement and feedback on key processes and outcomes of carotid endarterectomy (CEA).
Complete medical record (hospital chart) review for indications, care processes, and outcomes was performed on a random sample of Medicare patients undergoing CEA in 10 states (Arkansas, Georgia, Illinois, Indiana, Iowa, Kentucky, Michigan, Nebraska, Ohio, Oklahoma) during baseline (Jun 1, 1995 to May 31, 1996) and remeasurement (Jun 1, 1998 to May 31, 1999) periods. In addition to review of the index hospital stay, hospital admissions within 30 days of the procedure were reviewed and the Medicare enrollment database queried to identify out-of-hospital deaths, to determine 30-day outcome results. The baseline data by state were provided to the Medicare Quality Improvement Organizations (QIOs) in the respective states, and quality improvement initiatives were encouraged.
We reviewed 9945 primary CEA alone procedures, 236 CEA and coronary artery bypass grafting (CABG) procedures, and 380 repeat CEA operations during the baseline period (B), and 9745 primary CEA alone procedures, 233 CEA and CABG procedures, and 401 repeat CEA operations during the remeasurement period (R). There was a significant decrease in the combined event rate (30-day stroke or mortality) for CEA alone procedures between baseline and remeasurement (B, 5.6%; R, 5.0%). A decrease occurred in each of the indication strata; transient ischemic attack or stroke (B, 7.7%; R, 6.9%), nonspecific symptoms (B, 5.9%; R, 5.4%), and no symptoms (B, 4.1%; R, 3.8%). The combined event rate also decreased for CEA and CABG (B, 17.4%; R, 13.3%) and repeat CEA operations (B, 6.8%; R, 5.7%). The remeasurement period state-to-state variation in combined event rate for CEA alone ranged from 2.7% (Georgia) to 5.9% (Indiana) for all indications combined, from 4.4% (Georgia) to 10.9% (Michigan) in patients with recent transient ischemia or stroke, from 1.4% (Georgia) to 6.0% (Oklahoma) in patients with no symptoms, and from 3.7% (Georgia) to 7.9% (Indiana) in patients with nonspecific symptoms. There were significant increases in preoperative antiplatelet administration (62%-67%; P <.0001) and patching (29%-45%; P =.05) from baseline to remeasurement in the CEA alone subset. Preoperative antiplatelet administration and patching were associated with improved outcomes in the combined baseline and remeasurement data.
Community-wide quality improvement initiatives with performance measurement and confidential reporting of provider level data can lead to improvement in important care processes and outcomes. There is considerable variation between states in outcome and process, and thus continued room for improvement. Quality improvement projects that include standardized confidential outcome reporting should be encouraged. Preoperative antiplatelet therapy administration and patching rates should be considered as evidence-based performance measures.
本研究旨在评估社区范围内的绩效评估与反馈对颈动脉内膜切除术(CEA)关键流程及结果的影响。
对10个州(阿肯色州、佐治亚州、伊利诺伊州、印第安纳州、爱荷华州、肯塔基州、密歇根州、内布拉斯加州、俄亥俄州、俄克拉荷马州)接受CEA的医疗保险患者进行随机抽样,在基线期(1995年6月1日至1996年5月31日)和复测期(1998年6月1日至1999年5月31日)对其完整病历(医院病历)进行回顾,以了解手术指征、护理流程及结果。除了回顾索引住院期间的情况,还对术后30天内的医院再入院情况进行了回顾,并查询医疗保险注册数据库以确定院外死亡情况,从而确定30天的结果。各州的基线数据已提供给相应州的医疗保险质量改进组织(QIO),并鼓励开展质量改进举措。
在基线期(B),我们回顾了9945例单纯CEA手术、236例CEA联合冠状动脉旁路移植术(CABG)手术以及380例CEA再次手术;在复测期(R),回顾了9745例单纯CEA手术、233例CEA联合CABG手术以及401例CEA再次手术。单纯CEA手术的联合事件发生率(30天内中风或死亡)在基线期和复测期之间显著降低(B期为5.6%;R期为5.0%)。各指征分层均出现下降;短暂性脑缺血发作或中风(B期为7.7%;R期为6.9%)、非特异性症状(B期为5.9%;R期为5.4%)以及无症状(B期为4.1%;R期为3.8%)。CEA联合CABG手术以及CEA再次手术的联合事件发生率也有所下降(B期为17.4%;R期为13.3%;B期为6.8%;R期为5.7%)。复测期内,单纯CEA手术联合事件发生率在各州之间的差异为:所有指征综合起来,从2.7%(佐治亚州)到5.9%(印第安纳州);近期有短暂性脑缺血发作或中风的患者,从4.4%(佐治亚州)到10.9%(密歇根州);无症状患者,从1.4%(佐治亚州)到6.0%(俄克拉荷马州);非特异性症状患者,从3.7%(佐治亚州)到7.9%(印第安纳州)。在单纯CEA亚组中,从基线期到复测期,术前抗血小板药物的使用显著增加(从62%增至67%;P <.0001),补片使用也显著增加(从29%增至45%;P =.05)。在基线期和复测期合并数据中,术前抗血小板药物的使用和补片使用与改善的结果相关。
社区范围内的质量改进举措,包括绩效评估以及对医疗服务提供者层面数据的保密报告,可促使重要护理流程及结果得到改善。各州在结果和流程方面存在相当大的差异,因此仍有改进空间。应鼓励开展包括标准化保密结果报告的质量改进项目。术前抗血小板治疗的使用和补片使用率应被视为基于证据的绩效指标。